Natixis Advisors L.P. Has $140.17 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Natixis Advisors L.P. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 141.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,129,570 shares of the medical device company’s stock after acquiring an additional 661,584 shares during the quarter. Natixis Advisors L.P. owned 0.29% of DexCom worth $140,168,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Sands Capital Management LLC grew its stake in shares of DexCom by 4.3% in the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after buying an additional 557,543 shares in the last quarter. Blair William & Co. IL raised its position in shares of DexCom by 1.7% in the third quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock valued at $420,517,000 after buying an additional 73,654 shares in the last quarter. Northern Trust Corp raised its holdings in DexCom by 2.4% in the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after acquiring an additional 91,249 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in DexCom by 1.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,160,961 shares of the medical device company’s stock worth $201,618,000 after buying an additional 28,621 shares in the last quarter. Finally, Winslow Capital Management LLC bought a new stake in shares of DexCom during the 3rd quarter worth $173,120,000. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the sale, the executive vice president now owns 68,682 shares in the company, valued at approximately $9,618,227.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the transaction, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,375 shares of company stock worth $25,530,859. Corporate insiders own 0.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Raymond James lifted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Finally, Royal Bank of Canada began coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Trading Down 0.1 %

Shares of DXCM traded down $0.10 during trading hours on Thursday, reaching $125.78. 1,033,821 shares of the company traded hands, compared to its average volume of 3,030,949. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The company’s fifty day moving average price is $131.68 and its two-hundred day moving average price is $119.57. The company has a market capitalization of $50.02 billion, a price-to-earnings ratio of 80.84, a price-to-earnings-growth ratio of 2.18 and a beta of 1.23.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Equities research analysts predict that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.